Global Oncology | Specialty

The OncLive® Global Oncology condition center page is a comprehensive resource for clinical news and international expert insights on treatment of patients with cancer. This page features articles focused on ex-US regulatory news, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing global research in oncology care.

EMA Accepts Application for Enfortumab Vedotin in Locally Advanced or Metastatic Urothelial Cancer

March 26th 2021

The European Medicines Agency has accepted a marketing authorization application for enfortumab vedotin-ejfv for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor and a platinum-containing chemotherapy in the neoadjuvant or adjuvant, locally advanced or metastatic setting.

Adagrasib Demonstrates Favorable Efficacy, Pharmacokinetic Profile in Advanced KRAS G12C+ NSCLC

March 25th 2021

Adagrasib yielded durable responses and broad disease control, in addition to providing extensive predicted coverage throughout the dosing interval, in patients with KRAS G12C–mutant advanced non–small cell lung cancer.

Pemigatinib Approved in Japan for Unresectable, FGFR+ Biliary Tract Cancer

March 23rd 2021

The Japanese Ministry of Health, Labour, and Welfare has approved pemigatinib for the treatment of patients with unresectable biliary tract cancer with a FGFR2 fusion gene, worsening following chemotherapy.

CA-125 Level Informs Surveillance Strategy for Olaparib/Bevacizumab in Ovarian Cancer

March 19th 2021

CA-125 surveillance alone could be used to detect disease progression in patients with advanced ovarian cancer and an abnormal CA-125 level at the beginning of frontline maintenance therapy with olaparib and bevacizumab, according to an analysis from the phase 3 PAOLA-1.

Dr. Hurley on Breast Cancer Baseline Characteristics in the Caribbean Vs the United States

March 18th 2021

Judith E. Hurley, MD, discusses the baseline characteristics of patients with breast cancer in the Caribbean vs those in the United States.

Companies Collaborate to Develop Companion Diagnostic for Immunotherapy in HPV-Associated Cervical Dysplasia

March 18th 2021

QIAGEN and INOVIO Pharmaceuticals, Inc. are extending their collaborative efforts with a new agreement to develop liquid biopsy–based companion diagnostic assays for INOVIO agents, according to a news release from INOVIO.

Daratumumab Plus Rd Prolongs PFS in Frail, Newly Diagnosed, Transplant-Ineligible Myeloma

March 18th 2021

The addition of daratumumab to lenalidomide and dexamethasone resulted in improved progression-free survival vs Rd alone in patients with newly diagnosed multiple myeloma who were not eligible for transplant—even in frail patients.

Pembrolizumab Approved in Europe for Adult and Pediatric Relapsed/Refractory Classical Hodgkin Lymphoma

March 17th 2021

The European Commission has approved an expanded label for pembrolizumab for use as a single agent in the treatment of select adult and pediatric patients aged 3 years and older who have relapsed/refractory classical Hodgkin lymphoma.

NICE Recommends Against Olaparib for Metastatic Prostate Cancer

March 8th 2021

The United Kingdom’s National Institute for Health and Care Excellence will not recommend olaparib for the treatment of patients with hormone-relapsed, metastatic prostate cancer that harbors BRCA1 or BRCA2 mutations that has progressed on abiraterone acetate or enzalutamide.

Teclistamab Shows Continued Promise in Relapsed/Refractory Multiple Myeloma

March 8th 2021

Teclistamab demonstrated encouraging clinical activity, along with a tolerable safety profile, in patients with relapsed/refractory multiple myeloma.

Maintenance Lenalidomide Safe, Should Be Continued in Patients With Myeloma Who Contract COVID-19

March 5th 2021

Maintenance treatment with lenalidomide was found to be a safe treatment for patients with multiple myeloma who are diagnosed with COVID-19, supporting use of the immunomodulatory drug in this patient population.

Melphalan Triplets Elicit Responses, Are Safe in Relapsed/Refractory Multiple Myeloma

March 5th 2021

The triplet regimen of melphalan flufenamide with dexamethasone and either daratumumab or bortezomib demonstrated encouraging clinical activity and was well tolerated in patients with heavily pretreated relapsed/refractory multiple myeloma.

Ixazomib Triplets Show Efficacy in Transplant-Ineligible Newly Diagnosed Multiple Myeloma

March 4th 2021

Ixazomib-based triplet regimens as induction therapy elicited higher rates of efficacy compared with ixazomib/dexamethasone alone, followed by single-agent ixazomib maintenance, in patients with transplant-ineligible newly diagnosed multiple myeloma.

Zanubrutinib Approved in Canada for Waldenström Macroglobulinemia

March 2nd 2021

Health Canada has approved the BTK inhibitor zanubrutinib for the treatment of adult patients with Waldenström macroglobulinemia.

Dostarlimab Gets Positive EU Opinion in Recurrent or Advanced MSI-H Endometrial Cancer

February 26th 2021

February 26, 2021 - The European Medicines Agency’s Committee for Medicinal Products for Human Use granted a positive opinion to dostarlimab as a treatment for patients with recurrent or advanced microsatellite instability–high/mismatch repair deficient endometrial cancer who have progressed on or following platinum-based chemotherapy.

Cabozantinib/Nivolumab Approaches EU Approval for Frontline Advanced RCC

February 26th 2021

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for the combination of cabozantinib plus nivolumab for use as a frontline treatment in patients with advanced renal cell carcinoma.

Dr. Kulasinghe on Identifying COVID-19–Associated Gene Signatures Through Spatial Transcriptomics

February 26th 2021

Arutha Kulasinghe, PhD, discusses identifying COVID-19–associated gene signatures through spatial transcriptomics.

Dr. Lavery on Cancer Care in Ireland Amidst the COVID-19 Pandemic

February 26th 2021

Anita Lavery, MD, MRCP, discusses the current state of cancer care during the COVID-19 pandemic in Ireland.

Dr. Garassino on COVID-19 Vaccine Distribution to Patients With Cancer in Italy

February 25th 2021

Marina Garassino, MD, discusses the distribution of the coronavirus disease 2019 vaccine to patients with cancer in Italy.

Dr. Kulasinghe on Cancer Care During the COVID-19 Crisis in Australia

February 19th 2021

Arutha Kulasinghe, PhD, discusses cancer care during the coronavirus disease 2019 pandemic in Australia.